研究结果:HIV PrEP队列(n=327)和HIV感染者队列(n=174)细菌性STI的相对风险(RR)均有所降低,包括淋病(RR 0.45,95%CI:0.34~0.65;RR 0.45,95%CI:0.34~0.65)、衣原体(RR 0.12,95%CI:0.05~0.25;RR 0.26,95%CI:0.12~0.57)和梅毒(RR 0.13,95%CI:0.03~0.59;RR 0.23,95%CI:0.04~1.29)。 法国ANRS D...
研究结果:HIV PrEP队列(n=327)和HIV感染者队列(n=174)细菌性STI的相对风险(RR)均有所降低,包括淋病(RR 0.45,95%CI:0.34~0.65;RR 0.45,95%CI:0.34~0.65)、衣原体(RR 0.12,95%CI:0.05~0.25;RR 0.26,95%CI:0.12~0.57)和梅毒(RR 0.13,95%CI:0.03~0.59;RR 0.23,95%CI:0.04~1.29)。 法国ANRS D...
美国CDC在2017年9月发布的一份备忘录中表示,当艾滋病感染者接受抗病毒疗法后,保持稳定和高质量的服药依从性,使血液中病毒量降至200 copies/ml以下,或是低至仪器检测不到的状况下,在性行为时传染风险甚至可以忽略。 备忘录中指出,有三项不同研究,研究数千对伴侣、数千次未戴套或HIV暴露前预防性服药(PrEP)的性...
Citing agrowing supply of the shots, federal health officials said they are now moving to a "pre-exposure prophylaxis" or PrEP approach to vaccine eligibility — meaning offering it to people as a preventive measure before they had any known exposure. Previously, the CDC had only recommended th...
The article presents information about ChioraPrep, which is a preoperative skin preparatory. The product is the first U.S. Food and Drug Administration approved presurgical topical agent that ...
October 17, 2024 · 2 min read · Annalee Armstrong Layoffs Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D October 17, 2024 · 2 min read · Angela Gabriel Infectious disease GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground ...
摘要: Reveals that Centers for Disease Control and Prevention's (CDC) strong recommendation for zidovudine in combination with lamivudine to treat health workers stuck with a needle used to treat a HIV-positive patient. Average risk of HIV infection from all types of needlestick; Emergency departme...
CD4+ T cells can "help” or "license” conventional type 1 dendritic cells (cDC1s) to induce CD8+ cytotoxic T lymphocyte (CTL) anticancer responses, as proven in mouse models. We recently identified cDC1s with a transcriptomic imprint of CD4+ T-cell help
当提供Doxy PEP时,应结合全面性健康方法来实施,包括降低风险咨询、STI筛查和治疗、推荐疫苗接种,以及与HIV PrEP、HIV照护或其他适当服务的联系。接受Doxy PEP治疗的个体,应在基线时和此后每3~6个月进行暴露部位的细菌性STI检测。应根据当前建议为HIV阴性的MSM和TGW进行HIV筛查。
研究对象:232名HIV阴性的MSM和跨性别女性(TGW),同时使用替诺福韦和恩曲他滨(TDF/FTC)作为HIV的暴露前预防(PrEP)。 研究方法:参与者随机分配至:(1)多西环素200 mg单剂量口服,最好在无保护性行为后24小时内服用,最迟不超过72小时,每周最多三次...